Mindray Medical International (NYSE: MR) is expected to report Q2 earnings on Aug. 6. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Mindray Medical International's revenue will grow 19.1% and EPS will grow 11.9%.

The average estimate for revenue is $258.8 million. On the bottom line, the average EPS estimate is $0.47.

Revenue details
Last quarter, Mindray Medical International booked revenue of $219.0 million. GAAP reported sales were 21% higher than the prior-year quarter's $180.9 million.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.34. GAAP EPS of $0.31 for Q1 were 3.1% lower than the prior-year quarter's $0.32 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 54.9%, 20 basis points worse than the prior-year quarter. Operating margin was 16.8%, 150 basis points worse than the prior-year quarter. Net margin was 16.7%, 410 basis points worse than the prior-year quarter.

Looking ahead
The full year's average estimate for revenue is $1.05 billion. The average EPS estimate is $1.76.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,359 members out of 1,395 rating the stock outperform, and 36 members rating it underperform. Among 255 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 241 give Mindray Medical International a green thumbs-up, and 14 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mindray Medical International is outperform, with an average price target of $32.42.